







Levels of TNF-a in Petients with Congestive
Hesrt Fsilure
N.Galib,F.Grfgioni,V.Cetvi,S.Boschi,L.Uguccioni,G.Ussia,
P.Cafanzariti,A. Fucili,A. Branzi,B. Magnani.Instituteof Cardiology,
Universityof Bologna,Italy
The citokinetumor necrosisfactor-a(TNF-a)has bean impliestsdin the
pethogeneaiaof chronicheartfailure(CHF)aswellas in acuteandchronic
hearttransplantrejection.Thetime courseof plasmalevelsof TNF-awas
aaaesaadin 19 patientswith CHF(age54 + 7 years)beforehearttrans-
plantation(b-HTx)and 3, 6 and 12 monthsaftersurgery(HTx-3,-6, -12).
Bloodwas withdrawnfrom the antacubitelvein and a myocsrdialbiopsy
wasperformedwithin12 hours.TNF-czplasmalevelswereassessedalso
in 10age-matchedcontrolsubjects.Analysiswasperformedbya sandwitch
ELISAmethod.Statisti@were performedby ANOVA.The TNF-aplasma
Ievela(p@ml)wereasfollows:
Controls b-HTx HTX-3 HTX-6 HTX-12
6.74=3.3 28.1+ 10.7* 23.1+ 10,6* 23.2& 12.4’ 23+ 11.5*
ANOVA:p <0.0001.*p c 0.05vsControls.
In 5 myocardialbiopsiesof 5 differentpatientsa multifocalmoderate
rejection(grade3A or B of BillinghamScale)was deteetsd.The TNF-a
plasmalevelsin caseof grade3 rejectionwereincreasedwhencompared
to the levelsobservedin caaeof mild(grade1Aor B)andnorejeetion(40l
10.8VS20.7+ 8.9pg/ml,p < 0.05)andwhencomparedtotheb-HTxvalues
(p < 0.05).Nodifference wereobservedbetweenTNF-aplasmalevelsin




3Aor B)buttheyremainelevatedcomparedto the plasmalevelsof control
subjecfa;2) TNF-aplasmalevelsincreasemarkedlyin caseof grade3Aor
Bacuterejeefionalsoin comparisonto theb-HTxlevels.
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Endomyocerdialbiopsies(EMBa)in hearttransplantrecipientsareroutinely
performedin anattemptto detectsubclinicalepisodesof rejection.Bsesuse
episodesof rejectionoccurmorefrequentlyesrfyaftertransplantationand
thendecreasewithtime,it is unclearwhetherperformingsurveillanceEMBs
> 1 year post transplantationalters therapy.To investigatethe effectof
surveillanceEMBsonchangesin immunosuppressiontherapy,wereviewed
the resultaof 1949 EMBsperformedin 134consecutivehearttransplant
patientsbetween1989-1996.We performed1357 EMBs< 1 year post
transplantand592 in all subsequentyears.Histologicalscoresof rejection
that resultedin changesin therapyoccurredin 210of 1357(15.5%)EMBs
performedc 1 year,whereasOnly in 16 of 592 EMBs(2.7%)performed>





formed <1 yearbutnotthereafterresultin frequentremgnitionof rejection
episodesand consequentlychangesin immunosuppresaivetherapy,Our
data demonstratethat the utilityof obtainingsurveillanceEMBsfor clini-
cal decisionmakingdecreasesovertime and suggestthat > 1 year post
transplantonlyclinicallydrivenEMBsshouldbepetformed.
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lateaftertx. Yet,manypatients(pts)are absolutelyfree of Rej.Therefore,
we triadto identitypts lateafter tx who maynot needfurthersurveillance
endomyocardialbiopsies(EMB).in 112 pts (age 46 + 12 year+ with a
follow-upof z 3 years,a totalof4194EMBwereperformed.Ofthese,1364
wereperformedafterthe 2ndpost-txyear.EMBweredividedinto3 groups
accordingto theseverityof graftrejection:Rejectionscore(Rs)= O:ISHTO
or 1AorTexas*2; Rs= 1: ISHTIB or 2 or Texas3-4; Rs=2: ISHTz 3A
orTexasz 5. Whenconsideringall EMBz 2 yearsaftertx,sumof Ra(OR=
1.05perscorepoint),meancyclosporinelevelin thefirst2 yeare(cycle;OR
= 1.05perpercentof uppertherapeuticrange),age (OR= 0.96 paryear),
timeaftertx(OR=0.75peryear),cyclosporinelevelbelowtherapeuticrange
(OR= 1.75),and reductionof prsdnisone(OR= 1.97)were independent
predictorsof Rej(allp < 0.05).31 of 112(28%)ptshadat leastonefurther
Rej(mean1.7)afterthe”2ndpaat-txyear.Independentpredictorsidentifying
ptswithRejwerethesumof Rs(OR= 1.07),cycle(OR= 1.07),as wellas
recipientage(OR=0.96;allp < 0.05).Rss 17,age? 25yeara,andcyclos
90fhpercentileidentified52%of ptswhowouldnothaveneededEMBafter
the 2ndpost-fxyearwhereasthe other48% had a riskof 54%to develop
furtherRej.Cone/uaion.’Riskof Rejremainsconsiderablyhigh in somepts
evenlateafter&justifyingfurtherEMB.HoweverRs,cycloaftertx,andage
accuratelyidentify52%pts in whomEMBare no longernsceasaryas long
aaimmunosuppressivetherapyremainsunchanged.
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Allograffrejectionia a leadingcauaeof morbidityand mortalityfollowing
orfhotopichearttrensplantion.Rightventricularendomyocerdialbiopayis
thegoldstandardfordiagnosisof acutecellularrejection.Noninvasiveteat-
ing and serummarkershavebeenof limitedutility in pradietingrejaefion.
Thepresenceof Troponin-Tin the serumiaan accuratemarkerof myocyte
damagein patientswithiechemicsyndromea,but hasunknownclinicalutil-
ikyfor detectingrajsefion.Thisatudysoughtto determinethe accuracyof
Tro~nin-T to predicthigh-gradebiopsyprovencellularrejectionin trans-
plantrecipients.65consecutivepatientsunderwent127biopsies1 weekto




episodesweredefinedas:low-grade(S grade2); high-grade(~ 3A).
AllPatients >6 Monthsposttrsnsplsnt





Despitea lowsensitivity,serumTroponin-Tvaluesc 0.1 ng/dLprovide
an accuratenon-invasivemarkerfor identifyingpatientswithouthigh-grade
rejection.
w] pharmacOkinetic, BIOodPreasure, and Renal
Effects of Cyclosporine Sandimmune Vs Neoral
Formulation in Heart Transplant Recipients
M.White,G.B.Pelietier,C.Jeaina,M.Carrier.Montrea/Haarthrsfitute,
Montreal,Quebec,Canada
SandimmuneNsoral(C-NOO)is a newformulationof cyclosporineA (cycle)
